Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule experimental drug belonging to the pyrrolopyridine class. It acts as an inhibitor of cell division cycle 7-related protein kinase (CDC7), a kinase involved in the initiation of DNA replication by phosphorylating substrates that regulate the G1/S phase transition such as MCM proteins and CLASPIN. The inhibition of CDC7 suggests potential applications in targeting proliferative diseases like cancer. The compound has been referenced under PubMed ID 19115845 and is identified by DrugBank accession DB07149. No marketed brand names or approved indications are currently available; it remains an experimental agent primarily studied for its kinase inhibitory activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one.